P Poikonen

Summary

Affiliation: Helsinki University Central Hospital
Country: Finland

Publications

  1. ncbi Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 40:67-71. 2001
  2. ncbi Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel
    Paula Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 43:190-5. 2004
  3. ncbi Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, PO Box 180, 00029 HUS Helsinki, Finland
    Br J Cancer 93:515-9. 2005
  4. ncbi Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 80:1763-6. 1999

Detail Information

Publications4

  1. ncbi Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 40:67-71. 2001
    ..Therefore, the drug doses should not be reduced because of obesity, and even when obese patients are treated according to the scheduled doses they may remain slightly underdosed...
  2. ncbi Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel
    Paula Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Acta Oncol 43:190-5. 2004
    ....
  3. ncbi Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, PO Box 180, 00029 HUS Helsinki, Finland
    Br J Cancer 93:515-9. 2005
    ..Cyclin A is a good marker for tumour proliferation and prognosis in breast cancer. In the present study, cyclin A did not predict chemotherapy response...
  4. ncbi Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
    P Poikonen
    Department of Oncology, Helsinki University Central Hospital, Finland
    Br J Cancer 80:1763-6. 1999
    ..A low leucocyte nadir during the adjuvant CMF chemotherapy is associated with favourable DDFS and it may be a useful biological marker for chemotherapy efficacy...